Sign Up For Live
Surfing The NASH Tsunami Podcast now includes Live Audience attendance during recordings. We record Monday afternoons EST, with invites sent out on Fridays. Our host Roger Green will invite you into the epsiode to ask your questions and to address your feedback regarding anything and everything in Fatty Liver Disease. Our usual Surfers will also be there too… each week… every episode!
Do you have a quesiton you want to ask on this week's episode?

S2-E42.1 – FGF Drugs in Development – A Promising Class of Agents

Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation focuses on FGF drug development to date.

After a simple opening from Roger Green, this conversation about FGF drugs in Development includes 4 key elements:

1:05 – Roger Green discusses recent history of FGF agents and podcast episodes discussing them
2:11 – Stephen Harrison discusses the efruxifermin BALANCED Phase 2a trial in F2/F3 NASH and Cohort C with cirrhosis patients
6:59 – Arun Sanyal and Stephen Harrison discuss future prospects for FGF-21 agents
10:34 – Arun Sanyal discusses specific receptor targets for different FGF agents and why they matter

This episode has specific discussions of efruxifermin and mentions of pegbelfermin and MK-3655, the former NGM-313.

Request Transcript of This Episode
Request Transcript

Stay In Touch with Surfing NASH

Stay In Touch
  • Name
  • Email & NPI
  • Country
  • Institution & Profession